Mark Alles
Mark Alles is a former executive at Celgene, the pharmaceutical company behind Revlimid, a derivative of thalidomide. Under his leadership, the company faced scrutiny for its aggressive pricing strategies while promoting the drug as a life-saving therapy for multiple myeloma.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Celgene President Mark Alles sent an internal email complaining of disappointing first quarter Revlimid sales.
4